Mike Ryan
General Manager, Europe
Expertise:
With more than 25 years of experience in the life sciences industry, Mike has held global leadership positions in both clinical development and life sciences software companies. Given this experience, he is highly experienced in the use of technology and understands its impact in simplifying the process of developing and delivering novel therapies and making them more accessible to patients around the world. He has worked with many biotech and pharmaceutical companies to develop clinical pathways that deliver upon the ultimate commercial goals required to ensure success for all stakeholders. Mike speaks at many global industry events to promote the idea of innovation in healthcare and to encourage a greater level of partnership between healthcare stakeholders.
Articles by Mike Ryan
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Mike Ryan, General Manager, Europe, at EVERSANA, connected in a conversation with PharmaShots before Reuters Pharma 2025 in Barcelona, which ran 9-11 April 2025. Mike’s discussion focused on the history of EVERSANA and how the company helps bring strategies to market to help biopharmaceutical and pharma companies navigate the European market, regulatory landscapes, and much […]
Successfully Navigating the Complexity of Market Access Across Europe to Improve Health Equity
Navigating the complexities of bringing new drug therapies to market in Europe is a formidable challenge, especially with the diverse and fragmented reimbursement landscape across the EU’s 27 member states. In this insightful article published in European Biopharmaceutical Review, EVERSANA’s Mike Ryan and Paolo Correale delve into the intricacies of the European market access process, […]
Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders
Launching in today’s unpredictable market is a journey with new challenges around every corner. While product pipelines are rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build effective commercialization infrastructures, think globally, and launch products at unprecedented speeds, which comes at a steep price. In this […]
Launching in the EU/U.K.: The 7-Step Countdown to Success
THE LAUNCH Eager to explore the vast potential of launching your product in the EU/UK? While the mission is challenging, thorough preparations can ensure a smooth route to success. You only get one chance to launch, and studies have shown that two-thirds of launches did not reach their projected sales. If your launch is sub-optimal […]
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric”. This comprehensive guide provides insights into: The need for a unified, […]
In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts
Biotech enterprises, driven by the dual goals of treating a maximum patient population and ensuring a robust return on investment, must strategically navigate the complex landscape of global commercialization. Although the United States remains a crucial first market, most industry commentators agree that a nuanced strategy prioritizing global expansion is imperative. From a market size […]
European Parliament’s Revision of the General Pharmaceutical Legislation
The European Parliament has adopted a revision of the general pharmaceutical legislation, repealing and amending previous legislation with a set of compromise amendments. According to the European Commission, it has been called “the largest reform in over 20 years.” In this POV, EVERSANA’s experts, Mike Ryan, GM, Europe and Monique Martin, SVP, Value and Evidence, […]
Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies
In April, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 2022 Patient W.A.I.T Indicator found that the average rate of availability for pharmaceuticals in Europe is 45%, down 2% on the previous year. Additionally, the access gap between the highest and lowest country was found to be 83% in the 4-year cohort, and 80% […]
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of […]
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time […]
The Future of Pharma – A Provocative Perspective
In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Mike Ryan, Vice President, Europe, EVERSANA. They discuss the future of pharma and the impact of recent advancements in healthcare. The industry is facing a unique moment, with technology opening up new possibilities for medical interventions and a greater focus on […]